Volume | 977,604 |
|
|||||
News | (1) | ||||||
Day High | 71.25 | Low High |
|||||
Day Low | 66.95 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Intra Cellular Therapies Inc | ITCI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
71.12 | 66.95 | 71.25 | 67.00 | 71.21 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
15,800 | 977,604 | $ 68.49 | $ 66,957,359 | - | 45.50 - 84.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:47 | 1 | $ 67.64 | USD |
Intra Cellular Therapies (ITCI) Options Flow Summary
Intra Cellular Therapies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.48B | 96.81M | - | 464.37M | -139.67M | -1.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Intra Cellular Therapies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ITCI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 71.61 | 73.77 | 66.95 | 70.72 | 947,173 | -4.61 | -6.44% |
1 Month | 67.20 | 84.89 | 64.155 | 74.08 | 1,503,872 | -0.20 | -0.30% |
3 Months | 71.26 | 84.89 | 62.78 | 71.73 | 986,775 | -4.26 | -5.98% |
6 Months | 56.60 | 84.89 | 52.88 | 68.49 | 905,817 | 10.40 | 18.37% |
1 Year | 63.47 | 84.89 | 45.50 | 63.46 | 823,254 | 3.53 | 5.56% |
3 Years | 35.00 | 84.89 | 28.40 | 54.36 | 773,376 | 32.00 | 91.43% |
5 Years | 13.94 | 84.89 | 6.75 | 38.66 | 946,800 | 53.06 | 380.63% |
Intra Cellular Therapies Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |